Kaneka Acquires Japan Medical Device Technology
Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Minoru Tanaka)(TOKYO:4118) has acquired all shares of Japan Medical Device Technology Co., Ltd. (Headquarters: Kamimashiki-gun, Kumamoto; President: Shuzo Yamashita) (hereinafter JMDT), a developer and manufacturer of medical devices, on November 30, 2023, and made it a wholly owned subsidiary.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231206372197/en/
Stent before expansion (Photo: Business Wire)
Kaneka manufactures and sells endovascular catheters, which are devices used in the treatment of cardiac, peripheral vascular, and cerebrovascular diseases. In particular, stenting*1 for the treatment of coronary artery diseases such as atherosclerosis has a market worth 30 billion yen in Japan, and Kaneka is aiming to expand its business in this area.
JMDT has high technological capabilities in the research and development of coronary stents and is one of the leaders in the development of bioresorbable stents*2.
Coronary artery treatment usually involves the placement of a tubular metal mesh stent at the lesion to expand the lumen and restore blood flow. However, as the stent remains in the blood vessel, another stent often cannot be placed in the same location should restenosis recur. JMDT's bioresorbable stent is made of a biodegradable magnesium alloy, which prevents vessel blockage potentially caused by the stent remaining in the vessel. In addition, 95% of the stent is resorbed and taken up by the body 1.5 years after implantation, ensuring that it does not interfere with the treatment of restenosis.
*1. A stent is a small, expandable, and tubular metal mesh, often made of metals such as cobalt-chromium alloy or nickel-titanium alloy. It is a medical device that widens tubular parts of the human body (blood vessels, trachea, esophagus, duodenum, colon, biliary tract, etc.) from inside the lumen. They are mounted on a catheter and dilated inside arteries to treat narrowed or occluded coronary arteries or peripheral arteries in the lower extremities. Implanting a stent restores blood flow at the treatment site.
*2. JMDT's bioresorbable stent is made of a highly safe magnesium alloy and has a low risk of thrombosis with a thin (100 µm) yet fully expandable stent body. Its surface is coated with a layer that controls the degradation of the magnesium alloy and drug (Sirolimus) elution. Furthermore, it is currently the only bioresorbable stent in Japan that has progressed to the FIH (First In Human) trial for use in humans for the first time.
[Japan Medical Device Technology Co., Ltd.]
10 million yen
Kumamoto Techno Incubation Center Bldg. D, 2020-3 Tabaru,
Mashiki-machi, Kamimashiki-gun, Kumamoto, 861-2202
Research and development for coronary stents and commissioned development of other medical devices
Introduction video of the bioresorbable stent (by JMDT):
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Investors & Public Relations Department
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Opengear Launches Enhanced Technical Certification Program22.2.2024 07:00:00 CET | Press release
Opengear, a Digi International company (NASDAQ, DGII, www.digi.com) and provider of secure and Smart Out of Band management solutions, today announced the launch of its enhanced Technical Certification Program, aimed at empowering IT professionals and network engineers in the Opengear network of channel and distribution organizations with comprehensive technical expertise to address evolving network challenges on the First Day, Worst Day, and Every Day. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240221739136/en/ Opengear launches its enhanced Technical Certification Program, providing technical professionals with the knowledge and expertise required to effectively navigate and manage complex network infrastructures. (Graphic: Business Wire) Developed by Opengear's channel engineers, the Technical Certification Program is a robust e-learning initiative designed specifically to equip solution architects and sales engineers
Lenovo Group: Third Quarter Results 2023/2422.2.2024 05:26:00 CET | Press release
Lenovo GroupLimited (HKSE: 992) (ADR: LNVGY), together with its subsidiaries (‘the Group’), today announced third quarter results reporting Group revenue increasing 3% year-on-year to US$15.7 billion, and Group profitability improving quarter-to-quarter for the second time in a row. Net income was US$357 million on a non-Hong Kong Financial Reporting Standards (non-HKFRS) basis, with net income margin up 0.4% quarter-to-quarter to 2.3%. The Group’s diversified growth engines continued to deliver strong performance, with revenue from non-PC businesses accounting for 42% of Group revenue, up 1.3 points year-on-year. The consistent quarter-to-quarter improvements over past quarters have been driven by the resilience of the Group’s core businesses and the wider effectiveness of its ongoing transformation. The SSG business hit an important milestone of passing the US$2 billion revenue threshold, achieved a record high operating profit with operating margin of over 20% and grew revenue fr
BlueConic Named the Only Challenger in Inaugural 2024 Gartner® Magic Quadrant™ for Customer Data Platforms21.2.2024 18:33:00 CET | Press release
Market-leading customer data platform (CDP) BlueConic today announced that it has been recognized as the only Challenger in the inaugural Magic Quadrant for Customer Data Platforms. We believe this industry recognition marks a major milestone for CDPs and the maturity of the space on a global scale. BlueConic differentiates from other vendors for its: Privacy-by-design philosophy: Maintaining responsible data practices is essential for garnering consumer trust, but maintaining compliance with a patchwork of regulations is only getting more difficult. That’s why BlueConic has been built with privacy at the forefront. The platform has been purposely designed to collect first-party data in ways that ensures it is unified, actionable, and privacy-compliant. Collecting and using data within the framework of privacy regulations like GDPR and CCPA enables companies to build trust and deliver valuable customer experiences, while mitigating their consumer data risk at the same time. Easy-to-use
Bynder named a “Leader” in Digital Asset Management by independent research firm21.2.2024 17:58:00 CET | Press release
Bynder, the global, enterprise digital asset management (DAM) platform, has been named a “Leader” in The Forrester Wave™: Digital Asset Management Systems, Q1 2024 report by Forrester Research, Inc. Bynder received a top score in the revenue category, with the report stating that “Bynder invests to play a transformative role in the digital-first economy.” In the past two years since the last report was launched, Bynder has surpassed $130m in ARR, announced a majority investment from Thomas H. Lee Partners, made two acquisitions, developed its enterprise partner ecosystem, launched more than 45 out of the box integrations and expanded its suite of product offerings to include AI capabilities and other new innovations that are redefining DAM. According to a quote from a customer reference in the report “the AI search and smart filter system in Bynder simplifies the process of finding the exact assets you’re looking for.” These recent AI innovations have highlighted the company’s market l
Parse Biosciences Launches Evercode Whole Transcriptome Version 3, Boosting Usability and Performance21.2.2024 17:00:00 CET | Press release
Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced a significant update to the company’s flagship Evercode™ Whole Transcriptome products. Available to ship in mid-March, Evercode Whole Transcriptome version 3 kits offer researchers a more streamlined workflow, more flexible and higher throughput fixation, and optimized reagents for improved sensitivity in gene detection. With the new version, customers will enjoy a more streamlined and flexible workflow, helping them move from samples to results more quickly. These enhancements are delivered while significantly improving upon the previous version’s sensitivity and library complexity, giving researchers higher biological resolution and insight into their samples. Parse customers already rely on the utility of Evercode fixation, which enables them to fix cells or nuclei when they become available, store them for up to six months, and then sequence them when ready. Fixation i